Our data demonstrate that riluzole can display synergistic anti-GBM effects with mTOR inhibitors (see Figure 5C) and recent data have demonstrated that riluzole synergizes with the chemotherapeutic paclitaxel in triple-negative breast cancers [53]. The gene discussed is MTOR; the disease is triple-negative breast carcinoma.